Rein Therapeutics, Inc. lost $1.96 per diluted share in fiscal year 2025. This represents an increase of 44.2% from the prior fiscal year. The table below carries 11 fiscal years, from 2015 to 2025, and the quarters Rein Therapeutics, Inc. has filed alongside them.
FY2025 annual
EPS (Diluted)-$1.96
YoY+44.2%
Source SEC Filings (10-K/10-Q)Latest period Q2 FY2026, ended Jun 30, 2026ReportedCurrency USD
Annual figures, oldest first. Point at a bar to read its period.
RNTX EPS (Diluted) by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.
What was Rein Therapeutics, Inc.'s diluted earnings per share in fiscal year 2025?
Rein Therapeutics, Inc. lost $1.96 per diluted share in fiscal year 2025.
How fast is Rein Therapeutics, Inc.'s diluted earnings per share growing?
Rein Therapeutics, Inc. (RNTX) diluted earnings per share rose by 44.2% year over year, from -$3.51 to -$1.96 in fiscal year 2025.
What was Rein Therapeutics, Inc.'s diluted earnings per share in the most recent quarter?
Rein Therapeutics, Inc. (RNTX) reported -$0.10 in diluted earnings per share in Q2 2026.
What does diluted earnings per share mean on a financial statement?
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what Rein Therapeutics, Inc. (RNTX) reported on that line in every period on record.
